Small molecule polypeptide for preventing and restraining inflammation and application of same
AssigneesXun XU, Yan XU, Shanghai First People's Hospital
InventorsXun XU, Yan XU, Qiao SUN
Life of this patent
Estimating the term…
Abstract
The present invention provides a polypeptide that is rich in leucine and used for preventing and restraining inflammation, and an application of same. The present invention further provides a method for preparing the polypeptide and a pharmaceutical composition containing the polypeptide. The advantage of the polypeptide comprises: small molecular weight, so as to permeate various eye tissue barriers; high water solubility, so as to have high dissolubility in neutral tears, aqueous humor and vitreous humor; and simple synthesis, so as to have a low preparation cost.
Claims13
A polypeptide of Formula I, or a pharmaceutically acceptable salt thereof
- (I)
- [Xaa0]-[Xaa1]-[Xaa2]-[Xaa3]-[Xaa4]-[Xaa5]-[Xaa6]-
- [Xaa7]-[Xaa8] [Xaa9]-[Xaa10]-[Xaa11]-[Xaa12]-
- [Xaa13]-[Xaa14]-[Xaa15]-[Xaa16]-[Xaa17]-[Xaa18]-
- [Xaa19]-[Xaa20]-[Xaa21]-[Xaa22]-[Xaa23]
- wherein,
- Xaa0 is absent, or a peptide segment consisting of 1-3 amino acids;
- Xaa1 is selected from the group consisting of Leu, Ile, Val, Met, Ala and Phe;
- Xaa2 is selected from the group consisting of Asp, Glu, Cys and Ser;
- Xaa3 is selected from the group consisting of Leu, Ile, Val, Met, Ala and Phe;
- Xaa4 is selected from the group consisting of Ser and Thr;
- Xaa5 is selected from the group consisting of His, Arg, Gl, Lys, Arg, Glu and Asp;
- Xaa6 is selected from the group consisting of Asn, Gln, His, Thr, Ser, Lys, Arg, Cys and Ser;
- Xaa7 is selected from the group consisting of Ser, Thr, Pro and Ala;
- Xaa8 is selected from the group consisting of Ile, Leu, Val, Met, Ala and Phe;
- Xaa9 is selected from the group consisting of Ser, Thr, Glu and Asp;
- Xaa10 is selected from the group consisting of Gln, Asn, Pro and Ala;
- Xaa11 is selected from the group consisting of Glu, Asp, Pro and Ala;
- Xaa12 is selected from the group consisting of Ser and Thr;
- Xaa13 is selected from the group consisting of Ala, Val, Leu and Ile;
- Xaa14 is selected from the group consisting of Leu, Ile, Val, Met, Ala, Phe, Thr and Ser;
- Xaa15 is selected from the group consisting of Tyr, Trp, Phe, Thr, Ser, Lys, Gln and Asn;
- Xaa16 is selected from the group consisting of Leu, Ile, Val, Met, Ala and Phe;
- Xaa17 is selected from the group consisting of Leu, Ile, Val, Met, Ala, Phe, Cys and Ser;
- Xaa18 is selected from the group consisting of Glu, Asp, Ala, Val and Ile;
- Xaa19 is selected from the group consisting of Thr and Ser;
- Xaa20 is selected from the group consisting of Leu, Ile, Val, Met, Ala and Phe;
- Xaa21 is selected from the group consisting of Pro, Ala, Lys and Arg;
- Xaa22 is selected from the group consisting of Ser, Thr, Asp and Glu;
- Xaa23 is absent, or a peptide segment consisting of 1-3 amino acids;
- and the polypeptide exhibits an activity of inhibiting inflammation.
Dependencies are inferred from the claim text.